Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion type Assertion NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_head.
- NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_provenance.
- NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion evidence source_evidence_literature NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_provenance.
- NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion SIO_000772 24754246 NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_provenance.
- NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion wasDerivedFrom befree-2016 NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_provenance.
- NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion wasGeneratedBy ECO_0000203 NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_provenance.